| __timestamp | Novavax, Inc. | Viking Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 19928000 | 1244910 |
| Thursday, January 1, 2015 | 30842000 | 5029636 |
| Friday, January 1, 2016 | 46527000 | 4846776 |
| Sunday, January 1, 2017 | 34451000 | 5329003 |
| Monday, January 1, 2018 | 34409000 | 7121000 |
| Tuesday, January 1, 2019 | 34417000 | 9128000 |
| Wednesday, January 1, 2020 | 145290000 | 10731000 |
| Friday, January 1, 2021 | 298358000 | 10701000 |
| Saturday, January 1, 2022 | 488691000 | 16121000 |
| Sunday, January 1, 2023 | 468946000 | 37021000 |
Data in motion
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. From 2014 to 2023, Novavax, Inc. and Viking Therapeutics, Inc. have shown contrasting approaches. Novavax's SG&A expenses surged by over 2,250% from 2014 to 2023, peaking in 2022. This reflects their aggressive expansion and investment in administrative capabilities. In contrast, Viking Therapeutics maintained a more conservative growth, with SG&A expenses increasing by approximately 2,870% over the same period, yet remaining significantly lower than Novavax's. This suggests a leaner operational model. As of 2023, Novavax's expenses were nearly 13 times higher than Viking's, highlighting their differing strategies. Investors and stakeholders should consider these trends when evaluating the companies' financial strategies and potential for sustainable growth.
Operational Costs Compared: SG&A Analysis of Novo Nordisk A/S and Novavax, Inc.
Novartis AG and Viking Therapeutics, Inc.: SG&A Spending Patterns Compared
Gilead Sciences, Inc. vs Novavax, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of argenx SE and Viking Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Viking Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Grifols, S.A. or Novavax, Inc.
Comparing SG&A Expenses: Amneal Pharmaceuticals, Inc. vs Viking Therapeutics, Inc. Trends and Insights
Viking Therapeutics, Inc. or Protagonist Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Viking Therapeutics, Inc. and Soleno Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Viking Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Breaking Down SG&A Expenses: MorphoSys AG vs Novavax, Inc.
Who Optimizes SG&A Costs Better? Arrowhead Pharmaceuticals, Inc. or Novavax, Inc.